Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 195

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Enhanced plasmacytoid dendritic cell antiviral responses after omalizumab

Open access
Gill, Michelle A., Liu, Andrew H., Calatroni, Agustin, Krouse, Rebecca Z., Shao, Baomei, Schiltz, Allison, Gern, James E., Togias, Alkis, Busse, William W.·2018·Journal of Allergy and Clinical Immunology

Abstract

Background Atopy and viral respiratory tract infections synergistically promote asthma exacerbations. IgE cross‐linking inhibits critical virus‐induced IFN‐&agr; responses of plasmacytoid dendritic cells (pDCs), which can be deficient in patients with allergic asthma. Objective We sought to determine whether reducing IgE levels in vivo with omalizumab treatment increases pDC antiviral IFN‐&agr; responses in inner‐city children with asthma. Methods PBMCs and pDCs isolated from children with exacerbation‐prone asthma before and during omalizumab treatment were stimulated ex vivo with rhinovirus and influenza in the presence or absence of IgE cross‐linking. IFN‐&agr; levels were measured in supernatants, and mRNA expression of IFN‐&agr; pathway genes was determined by using quantitative RT‐PCR (qRT‐PCR) in cell pellets. Fc&egr;RI&agr; protein levels and mRNA expression were measured in unstimulated cells by using flow cytometry and qRT‐PCR, respectively. Changes in these outcomes and associations with clinical outcomes were analyzed, and statistical modeling was used to identify risk factors for asthma exacerbations. Results Omalizumab treatment increased rhinovirus‐ and influenza‐induced PBMC and rhinovirus‐induced pDC IFN‐&agr; responses in the presence of IgE cross‐linking and reduced pDC surface Fc&egr;RI&agr; expression. Omalizumab‐induced reductions in pDC Fc&egr;RI&agr; levels were significantly associated with a lower asthma exacerbation rate during the outcome period and correlated with increases in PBMC IFN‐&agr; responses. PBMC Fc&egr;RI&agr; mRNA expression measured on study entry significantly improved an existing model of exacerbation prediction. Conclusions These findings indicate that omalizumab treatment augments pDC IFN‐&agr; responses and attenuates pDC Fc&egr;RI&agr; protein expression and provide evidence that these effects are related. These results support a potential mechanism underlying clinical observations that allergic sensitization is associated with increased susceptibility to virus‐induced asthma exacerbations.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jaci.2017.07.035

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 195

Metadata

Authors
Gill, M. A., Liu, A. H., Calatroni, A., Krouse, R. Z., Shao, B., Schiltz, A., Gern, J. E., Togias, A., & Busse, W. W.
Venue
Journal of Allergy and Clinical Immunology
Publisher
Elsevier BV
Published
2018-05
Volume
141
Issue
5
Pages
1735-1743.e9
ISSN
0091-6749 (ISSN-L)
OpenAlex
W2751934223
Cited by
195
References
5
FWCI
12.88
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Enhanced plasmacytoid dendritic cell antiviral responses after omalizumab. https://app.cochat.ai/papers/10.1016/j.jaci.2017.07.035
The paper
Gill, M. A., Liu, A. H., Calatroni, A., Krouse, R. Z., Shao, B., Schiltz, A., Gern, J. E., Togias, A., & Busse, W. W. (2018). Enhanced plasmacytoid dendritic cell antiviral responses after omalizumab. Journal of Allergy and Clinical Immunology. https://doi.org/10.1016/j.jaci.2017.07.035

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.